<DOC>
	<DOC>NCT02634320</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).</brief_summary>
	<brief_title>A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Aripiprazole lauroxil</mesh_term>
	<criteria>Has demonstrated tolerability to test doses of oral aripiprazole during screening; OR has a history of tolerated use of aripiprazole Has a diagnosis of schizophrenia Is clinically stable Has received at least 3 doses of risperidone long acting injection (Risperdal Consta) or paliperidone palmitate (Invega Sustenna) prior to screening. Has no antipsychotic medication regimen change for 4 weeks prior to Day 1 Agreed to abide by the contraceptive requirements o the protocol Resides in a stable living situation Additional criteria may apply Is currently pregnant or breastfeeding, or is planning to become pregnant during the study Has received Invega Trinza, aripiprazole lauroxil, or IM depot aripiprazole within 6 months of screening Has participated in a clinical trial involving any investigational product within the past 3 months, or is currently participating in a clinical trial involving an investigational product Has a positive urine drug test for illicit use of amphetamines, barbiturates, cocaine, methadone, opiates, phencyclidine at screening Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>ARISTADA</keyword>
	<keyword>Aripiprazole Lauroxil</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>